Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.60% is 15% above its 5-year average of 4.01%, near the high end of its 5-year range (1.14%–5.10%).
4.56% below its 12-month average of 4.82%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
4.60%
RETURN ON ASSETS (ROA) AVG TTM
4.82%
RETURN ON ASSETS (ROA) AVG 3Y
4.76%
RETURN ON ASSETS (ROA) AVG 5Y
4.01%
RETURN ON ASSETS (ROA) AVG 10Y
3.84%
RETURN ON ASSETS (ROA) AVG 15Y
4.87%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.56%
CURRENT VS 3Y AVG
-3.36%
CURRENT VS 5Y AVG
+14.57%
CURRENT VS 10Y AVG
+19.85%
CURRENT VS 15Y AVG
-5.52%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-10.51%
vs the sector median at left
IQVIA Holdings Inc.
Market Cap
$42.05B
Return on Assets (ROA)
4.60%
TTM Avg
4.82%
3Y Avg
4.76%
5Y Avg
4.01%
Market Cap
$42.85B
Return on Assets (ROA)
1.77%
TTM Avg
-0.35%
3Y Avg
-1.89%
5Y Avg
-2.43%
Market Cap
$41.06B
Return on Assets (ROA)
33.11%
TTM Avg
29.29%
3Y Avg
27.30%
5Y Avg
27.52%
Market Cap
$40.91B
Return on Assets (ROA)
10.31%
TTM Avg
10.56%
3Y Avg
11.14%
5Y Avg
10.55%
Market Cap
$49.69B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
Market Cap
$49.83B
Return on Assets (ROA)
7.25%
TTM Avg
19.91%
3Y Avg
18.29%
5Y Avg
17.04%
Market Cap
$34.07B
Return on Assets (ROA)
14.54%
TTM Avg
-0.12%
3Y Avg
-10.91%
5Y Avg
-15.37%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $42.05B | 4.60% | 4.82% | 4.76% | 4.01% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.85B | 1.77% | -0.35% | -1.89% | -2.43% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $41.06B | 33.11% | 29.29% | 27.30% | 27.52% |
| Agilent Technologies, Inc. (A)vs › | $40.91B | 10.31% | 10.56% | 11.14% | 10.55% |
| Humana Inc. (HUM)vs › | $47.93B | 2.23% | 2.52% | 4.20% | 5.49% |
| Becton, Dickinson and Company (BDX)vs › | $49.69B | 1.85% | 3.00% | 3.04% | 2.95% |
| Edwards Lifesciences Corporation (EW)vs › | $49.83B | 7.25% | 19.91% | 18.29% | 17.04% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.07B | 14.54% | -0.12% | -10.91% | -15.37% |
| Alcon Inc. (ALC)vs › | $33.58B | 2.06% | 3.23% | 2.72% | 1.72% |
| DexCom, Inc. (DXCM)vs › | $31.99B | 15.49% | 11.04% | 9.26% | 8.83% |
ROA
4.6%
ROE
22.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 4.54% |
| 2024-12-31 | 5.10% |
| 2023-12-31 | 5.09% |
| 2022-12-31 | 4.31% |
| 2021-12-31 | 3.91% |
| 2020-12-31 | 1.14% |
| 2019-12-31 | 0.82% |
| 2018-12-31 | 1.15% |
| 2017-12-31 | 5.76% |
| 2016-12-31 | 0.54% |
| 2015-12-31 | 9.86% |
| 2014-12-31 | 10.78% |
| 2013-12-31 | 7.39% |
| 2012-12-31 | 7.10% |
| 2011-12-31 | 10.41% |
| 2010-12-31 | 0.00% |
